Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone

Michael Segal, Avi Avital, Andrei Derevenski, Severina Berstein, Sergio Sandbank, Abraham Weizman

Research output: Contribution to journalArticlepeer-review


The frequently seen side effect of hyperprolactinemia thought to be the 'price' paid for the antipsychotic treatment of schizophrenia. Various reports have linked the use of risperidone, an atypical antipsychotic drug, with the significant rise of prolactin levels. Thus, we set to assess possible difference between prolactin levels among schizophrenia subtypes in 45 male patients treated with stable doses (2-6 mg/day) of risperidone as antipsychotic monotherapy. All patients showed increased prolactin levels beyond the normal range, with a significant difference between the paranoid and all other groups (P<0.0001). Specifically, the paranoid patients' prolactin levels were higher than those of the schizoaffective and the disorganized ones. These results suggest that the blockade of higher dopamine activity in the paranoid schizophrenia corresponds to the prolactin increase, more than in the schizoaffective and disorganized subtypes. These findings are opposite of what was observed in the previous study of unmedicated patients.

Original languageEnglish
Pages (from-to)192-196
Number of pages5
JournalInternational Clinical Psychopharmacology
Issue number4
StatePublished - Jul 2007
Externally publishedYes


  • Dopamine
  • Nonparanoid schizophrenia
  • Paranoid
  • Prolactin

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)


Dive into the research topics of 'Prolactin serum levels in paranoid versus nonparanoid male schizophrenia patients treated with risperidone'. Together they form a unique fingerprint.

Cite this